Personalized PRRT of Neuroendocrine Tumors

Neuroendocrine Tumors Clinical Trial

— P-PRRT  

Official title:

Personalized Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Phase 2 Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02754297
• Other study ID #: A14-11-2181
• Status: Recruiting
• Phase: Phase 2
• Start date: April 12, 2016
• Est. completion date: April 12, 2029

Study information

• Verified date: May 2023
• Source: CHU de Quebec-Universite Laval
• Contact: Jean-Mathieu Beauregard, MD,MSc,FRCPC
• Phone: 418-525-4444
• Email: medecine.nucleaire[@]mail.chudequebec.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study, peptide receptor radionuclide therapy (PRRT) with 177Lu-Octreotate (LuTate) will be personalized, i.e. administered activity of LuTate will be tailored for each patient to maximize absorbed radiation dose to tumor, while limiting that to healthy organs.

The purpose of this study is to:

• Assess the objective (radiological), symptomatic and biochemical response rates following an induction course of personalized PRRT;

• Assess the overall, the disease-specific, and the progression-free survival following P-PRRT;

• Correlate therapeutic response and survival with tumor absorbed radiation dose;

• Evaluate the acute, subacute and chronic adverse events following P-PRRT;

• Correlate toxicity (i.e. occurence and severity of adverse events) with absorbed radiation doses to organs at risk;

• Optimize the quantitative SPECT imaging-based dosimetry methods in a subset of 20 patients (sub-study funded by the Canadian Institutes of Health Research).

This study also has a compassionate purpose, which is to provide access to PRRT to patients.

Description:

A prospective, single-center, non-comparative, open phase 2 study. In this study, personalized peptide receptor radionuclide therapy (P-PRRT) with 177Lu-Octreotate (LuTate) will be administered to patients with progressive and/or symptomatic inoperable neuroendocrine tumors (NET) of any origin expressing the somatostatin receptor.

The primary objective to assess the objective response rate at 3 months following a four-cycle induction course of P-PRRT will be assessed for at least the first 85 participants.

This study as a compassionate aim to provide access to personalized PRRT patients at CHU de Québec - Université Laval center, and therefore this study has no pre-determined recruitment period duration or limited number of participants, and may remain open as long as necessary to fulfill this aim.

The study will continue until all participants have completed a minimum follow-up of 5 years. Interim analyses will be conducted annually.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: April 12, 2029
• Est. primary completion date: April 12, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient suffering from a progressive and/or symptomatic NET (any site);

• Patient ineligible to, or refusing a potentially curative treatment such as surgical resection;

• Patient who did not respond, is intolerant or refuses other indicated and available palliative treatments;

• Demonstration of overexpression of somatostatin receptor by tumor lesions by scintigraphic imaging (Octreoscan or 68Ga positron emission tomography.

Exclusion Criteria:

• Pregnancy;

• Breastfeeding;.

• Very limited survival prognosis (i.e. less than a few weeks, because of the NET disease or any other condition) or Eastern Cooperative Oncology Group (ECOG) 4 performance status;

• Inability to obtain informed consent of the participant.

Related Conditions & MeSH terms

• Carcinoid Tumor
• Carcinoma, Neuroendocrine
• Neoplasms
• Neuroendocrine Tumors

Intervention

Drug:
• 177Lu-Octreotate
The induction course will consist in 4 cycles at 8-10 weeks intervals. Concomitant amino acids will be administered for renal protection. Intra-arterial LuTate administration will be allowed in suitable cases. Dosimetry will be based on quantitative SPECT/CT imaging. In patients with hormonal symptoms, somatostatine analogues can be given between P-PRRT cycles.

Locations

Country	Name	City	State
Canada	CHU de Québec - Université Laval	Quebec City	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
CHU de Quebec-Universite Laval

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Tumor radiation dose-response relationship	Correlation between cumulative absorbed radiation dose to tumor lesions and 3-month objective response rate, as defined above	3 months after induction course
Other	Tumor radiation dose-survival relationship	Correlation between cumulative absorbed radiation dose to tumor lesions and survival endpoints above (PFS and OS)	At least 5 years after first cycle or until study completion, whichever came first
Other	Renal radiation dose-chronic toxicity relationship	Correlation between cumulative absorbed radiation dose to kidney and variations in glomerular filtration rate from baseline, reported annually for at least 5 years after first cycle or until study completion.	At least 5 years after first cycle or until study completion, whichever came first
Other	Bone marrow radiation dose-chronic toxicity relationship	Correlation between cumulative absorbed radiation dose to bone marrow and chronic variations of blood counts from baseline, reported annually for at least 5 years after first cycle or until study completion.	At least 5 years after first cycle or until study completion, whichever came first
Other	Bone marrow radiation dose-subacute toxicity relationship	Correlation between per-cycle absorbed radiation dose to bone marrow and subacute variations (nadir values between 2 and 6 weeks) of blood counts from baseline, for each cycle.	Time of nadir blood counts values between 2 and 6 weeks after each cycle
Primary	Objective response rate (ORR)	Primary efficacy endpoint is the objective response rate on contrast-enhanced CT (or MRI) by RECIST criteria (and secondarily by South Western Oncology Group (SWOG) criteria) at 3 months after the 4th induction cycle of P-PRRT, in comparison to pre-treatment scan (within 3 months before commencing P-PRRT).	3 months after induction course
Secondary	Progression-free survival (PFS)	Progression of disease is defined as the time from first cycle to the date of first documented progression of disease or death due to any cause. Progression of disease is defined by RECIST criteria.	Time from first cycle to date of disease progression or death, reported up to 5 years after accrual closure
Secondary	Overall survival (OS)		Time from first cycle to date of death, reported up to 5 years after accrual closure
Secondary	Symptomatic response rate	Proportion of participants with improved, stable or worsened NET-related symptoms (frequency and severity), based on participant interviews at baseline and 3 months after completion of induction course.	3 months after induction course
Secondary	Quality of life response	Proportion of participants with improved, stable or worsened quality of life score by EORTC quality of life questionnaires QLQ-C30 and QLQ-GI.NET21, administered at baseline and 3 months after induction course.	3 months after induction course
Secondary	Biochemical response	Proportion of participants with improved (decreased by 25% or more), stable or worsened (increased by 25% or more) Chromogranin-A serum levels performed at baseline and 3 months after induction course.	3 months after induction course
Secondary	Safety determined by type, frequency and severity of adverse events per CTCAE version 4.03 and type, frequency and severity of laboratory toxicities per CTCAE version 4.03		From the first treatment cycle administration until 5 years after accrual closure or death, whichever came first